|
1
|
Chen X, Ma S and Zhang Z: Analysis of
clinical characteristics of pancreatic carcinoma in northern China.
Pancreas. 39:1116–1118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Auriemma WS, Berger AC, Bar-Ad V, et al:
Locally advanced pancreatic cancer. Semin Oncol. 39:e9–e22. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar
|
|
4
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
|
|
5
|
Ungefroren H, Voss M, Jansen M, et al:
Human pancreatic adenocarcinomas express Fas and Fas ligand yet are
resistant to Fas-mediated apoptosis. Cancer Res. 58:1741–1749.
1998.PubMed/NCBI
|
|
6
|
Pitti RM, Marsters SA, Lawrence DA, et al:
Genomic amplification of a decoy receptor for Fas ligand in lung
and colon cancer. Nature. 396:699–703. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li W, Zhang C, Chen C and Zhuang G:
Correlation between expression of DcR3 on tumor cells and
sensitivity to FasL. Cell Mol Immunol. 4:455–460. 2007.PubMed/NCBI
|
|
8
|
Bamias G, Siakavellas SI, Stamatelopoulos
KS, Chryssochoou E, Papamichael C and Sfikakis PP: Circulating
levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3
(DcR3) in rheumatoid arthritis. Clin Immunol. 129:249–255. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gill RM and Hunt JS: Soluble receptor
(DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human
cytotrophoblast cells against LIGHT-mediated apoptosis. Am J
Pathol. 165:309–317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
You RI, Chang YC, Chen PM, et al:
Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3).
Blood. 111:1480–1488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL
and Lin WW: Soluble decoy receptor 3 induces angiogenesis by
neutralization of TL1A, a cytokine belonging to tumor necrosis
factor superfamily and exhibiting angiostatic action. Cancer Res.
64:1122–1129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang QL, Wang BR and Li GH: DcR3 and
survivin are highly expressed in colorectal carcinoma and closely
correlated to its clinicopathologic parameters. J Zhejiang Univ Sci
B. 10:675–682. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen C, Zhang C, Zhuang G, et al: Decoy
receptor 3 overexpression and immunologic tolerance in
hepatocellular carcinoma (HCC) development. Cancer Invest.
26:965–974. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Y, Guo E, Yu J and Xie Q: High DcR3
expression predicts stage pN2–3 in gastric cancer. Am J Clin Oncol.
31:79–83. 2008.
|
|
15
|
Arakawa Y, Tachibana O, Hasegawa M,
Miyamori T, Yamashita J and Hayashi Y: Frequent gene amplification
and overexpression of decoy receptor 3 in glioblastoma. Acta
Neuropathol. 109:294–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou J, Song SD, Li DC, Zhu DM and Zheng
SY: Clinical significance of expression and amplification of the
DcR3 gene in pancreatic carcinomas. Asian Pac J Cancer Prev.
13:719–724. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Y, Han B, Sheng H, et al: Clinical
significance of detecting elevated serum DcR3/TR6/M68 in malignant
tumor patients. Int J Cancer. 105:724–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song JH, Bellail A, Tse MC, Yong VW and
Hao C: Human astrocytes are resistant to Fas ligand and tumor
necrosis factor-related apoptosis-inducing ligand-induced
apoptosis. J Neurosci. 26:3299–3308. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gratas C, Tohma Y, Barnas C, Taniere P,
Hainaut P and Ohgaki H: Up-regulation of Fas (APO-1/CD95) ligand
and down-regulation of Fas expression in human esophageal cancer.
Cancer Res. 58:2057–2062. 1998.PubMed/NCBI
|
|
20
|
Meng Y, Graves L, Do TV, So J and Fishman
DA: Upregulation of FasL by LPA on ovarian cancer cell surface
leads to apoptosis of activated lymphocytes. Gynecol Oncol.
95:488–495. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abbasova SG, Vysotskii MM, Ovchinnikova
LK, et al: Cancer and soluble FAS. Bull Exp Biol Med. 148:638–642.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morishige T, Yoshioka Y, Inakura H, et al:
Creation of a LIGHT mutant with the capacity to evade the decoy
receptor for cancer therapy. Biomaterials. 31:3357–3363. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takahashi M, Miura Y, Hayashi S, Tateishi
K, Fukuda K and Kurosaka M: DcR3-TL1A signalling inhibits
cytokine-induced proliferation of rheumatoid synovial fibroblasts.
Int J Mol Med. 28:423–427. 2011.PubMed/NCBI
|
|
24
|
Tsuji S, Hosotani R, Yonehara S, et al:
Endogenous decoy receptor 3 blocks the growth inhibition signals
mediated by Fas ligand in human pancreatic adenocarcinoma. Int J
Cancer. 106:17–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Migone TS, Zhang J, Luo X, et al: TL1A is
a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell
costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wan X, Zhang J, Luo H, et al: A TNF family
member LIGHT transduces costimulatory signals into human T cells. J
Immunol. 169:6813–6821. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tourneur L, Buzyn A and Chiocchia G: FADD
adaptor in cancer. Med Immunol. 4:12005. View Article : Google Scholar : PubMed/NCBI
|
